American cutaneous leishmaniasis in French Guiana: a retrospective comparison between liposomal amphotericin B and meglumine antimoniate

Br J Dermatol. 2020 Aug;183(2):389-391. doi: 10.1111/bjd.18964. Epub 2020 Mar 31.

Authors

A Senchyna¹, S Simon², H Cissé¹, M Ginouves², G Prevot², G Alcoba³, M Demar^{2

4}, P Couppie^{1

2}, R Blaizot^{1

2}

Affiliations

¹ Dermatology Department, Andrée Rosemon Hospital, Cayenne, French Guiana.
² EA 3593 Ecosystèmes Amazoniens et Pathologies Tropicales, University of French Guiana, Cayenne, French Guiana.
³ Division of Tropical and Humanitarian Medicine, Geneva University Hospitals, Geneva, Switzerland.
⁴ Laboratory of Parasitology and Mycology, National Reference Center for Cutaneous Leishmaniasis, Andrée Rosemon Hospital, Cayenne, French Guiana.

No abstract available

Publication types

Letter

MeSH terms

Amphotericin B
Antiprotozoal Agents*
French Guiana
Humans
Leishmaniasis, Cutaneous* / drug therapy
Meglumine Antimoniate / therapeutic use
Retrospective Studies
United States

Substances

Antiprotozoal Agents
liposomal amphotericin B
Meglumine Antimoniate
Amphotericin B